Join the team. Share the vision.

Location

The Park

Media Center

Contacts

The Facility

Advanced Technology
Partnerships Initiative

Partners

"What NCI wanted is to interface more effectively with the private sector and academic community. A common ground for building public/private partnerships. Space that would be incubator space where a company could come in, set up a laboratory project, work for a period of time along with our NCI scientists. These are novel approaches for a government facility. What will spring from this site will be not only be a place of great progress where scientists from the government, from private industry and academia will come together, but these discoveries that will occur here, and the new products that will come out of our drug development will certainly impact people around the world. We will develop along with industry partners, the new technologies that will lead to the earliest possible diagnosis of cancer. The science that happens here will build on a proud history of success against cancer"

—Dr. Niederhuber
Director of NCI

Source: NCI at Riverside Research Park Ground Breaking, November 12, 2008

Partners

Business development approach includes in-reach activity to National Cancer Institute programs and outreach activity to industry and academia—to bridge strategic R&D interests and priorities for synergistic partnerships, including collocation potential.

Partnerships
GE Global Research: Cooperative research and development agreement with NCI's Nanotechnology Characterization Laboratory (NCL), to accelerate the development of cutting-edge nanoparticle based imaging agents that have the potential to revolutionize the diagnosis and treatment of cancer and heart disease at much earlier stages. NCL will apply its leading-edge nanotechnology characterization tools to evaluate the safety and feasibility of GE's nanoparticle diagnostic imaging agents.	Silicon Kinetics: Research and development agreement with the protein chemistry laboratory to better understand how proteins interact in cancer and AIDS and how drug interventions affect protein interactions. The 3-Dimensional, label-free Ski Pro™ Bimolecular Interaction Analysis Platform has the potential to provide new insights into cancer disease processes and the development of targeted therapeutics for cancer and infectious diseases.

Azaya Therapeutics: Research collaboration with NCI's Nanotechnology Characterization Laboratory (NCL) to study Azaya's lead cancer therapy, ATI-1123. Taxotere ® is a widely-prescribed chemotherapy drug, used for the treatment of breast, gastric, head and neck, ovarian, prostate, and non-small cell lung cancer. Studies will provide data to support Azaya's filings with the FDA.	Lankenau Institute For Medical Research/MIT: Research collaboration to perform preclinical studies on novel therapeutic nanoparticles for treatment of solid tumors. Initial Nanotechnology Characterization Laboratory (NCL) efforts will focus on the characterization of LIMR's product for its adsorption, distribution, and toxicity properties, in both in vitro and in vivo studies. This data will help to accelerate the LIMR/MIT team in filings with the U.S. Food and Drug Administration (FDA).

Ceres Nanotrap™: Collaboration agreement with NCI's Laboratory Proteomics Analytical Technologies to assess Ceres' nanotechnology-based system, Ceres Nanotrap™, a nanoparticle platform developed to better capture low-abundance biomarkers and protect them from degradation. Aim is to increase the speed and accuracy with which samples can be processed and analyzed, to lead to a better understanding of the role that steroid hormones play in cancer. Other Partnerships: Mayo Clinic Expression Pathology Roche NimbleGen Sporian Microsystems Princeton University Merck & Co. MedImmune	Sensor Technologies: Collaboration agreement to begin integrated studies of complex protein interactions involved in cancer and other diseases. The Optical Microscopy and Analysis Laboratory (OMAL) and Protein Chemistry Laboratory (PCL) will begin integrated studies to assess the dynamics of fluorescence-tagged molecules utilizing Sensor Technologies' newly launched Fluorescence Correlation Spectroscopy (FCS) platform — "QuantumXpert™". Studies will also include integration with in vivo microscopy techniques in OMAL with the goal of developing dynamic, bimolecular models that are both physical and performed by computer simulation. Applications of this technology have the potential to provide insights that could accelerate the development of new treatments and advance the field of computer simulation modeling in cancer research and development.